An observational study in Opioid-Related Disorders, NAS and Substance Use Disorders, sponsored by Trustees of Dartmouth College. Completed at 10 sites in United States. Open to female participants aged 16 Years to 50 Years. Per ClinicalTrials.gov, last updated 2026-10-23.
Sponsored by Trustees of Dartmouth College · Observational
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 1,223 studies in Opioid-Related Disorders with a site in United States — 246 open to participants now, 316 under way, 18 of them phase 3. Opioid-Related Disorders · United States.
Among the 1,223 studies in Opioid-Related Disorders with a site in United States, this one is the 13th largest by enrollment of the 122 observational ones that give a count, is one of 86 that started in 2019, is one of 122 observational ones, and was the 507th registered.
1,476 studies on the registry are indexed under Opioid-Related Disorders; 293 are open to participants now.
Browse Opioid-Related Disorders studies →246 of the 1,223 studies in Opioid-Related Disorders with a site in United States are open now. Recruiting first, the newest first:
Washington State University · Sites in United States
Ages 18+
University of Massachusetts, Worcester · Sites in United States
Ages 18+ · Healthy volunteers
Ohio State University · Sites in United States
Ages 21–65
University of Kentucky · Sites in United States
Ages 18–75
Baylor College of Medicine · Sites in United States
Ages 18–64
A study can be open while its sites in United States have not opened yet or have stopped. Only those recruiting at a site in United States →
Of the 213 Opioid-Related Disorders studies recruiting now, 123 (58%) set no upper age limit and 76 (36%) stop at 75 or younger; 14 take children under 18; 53 take healthy volunteers.
This study: 16 Years to 50 Years · female · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
1,223 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 162 · Phase 2 245 · Phase 3 99 · Phase 4 79
First in 1988; this study’s year is marked. 86 started in 2019.
By drug class, each counting the studies that test any of its medicines:
This study's enrollment of 2,510 is above the median of 129 across 184 observational studies indexed under Opioid-Related Disorders.
Median enrollment 56 across the 1,098 interventional studies, 85 across the 122 observational. Of the 834 that completed or were terminated, 332 (40%) have results posted.
This tab as a report to print or save as PDF → With an account.
132 of 1,223 have an industry lead sponsor. The 10 most frequent:
Trustees of Dartmouth College is the lead sponsor of 38 studies on the registry; 17 are open to participants now.
Trustees of Dartmouth College has 4 studies filed under Opioid-Related Disorders — fewer than ten, so there is no comparison to draw.
129 of the studies in Opioid-Related Disorders with a site in United States that are under way reach primary completion within a year, 9 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT05011266Phase 3New York State Psychiatric InstituteEfficacy of Buprenorphine and XR-Naltrexone Combination for Relapse Prevention in Opioid Use Disorder | 2027-01-01 |
| NCT05834478Phase 3Emory UniversityNon-invasive Vagal Nerve Stimulation in Opioid Use Disorders UH3 | 2027-02 |
| NCT05033028Phase 3NYU Langone HealthSmartphones for Opiate Addiction Recovery | 2027-06-01 |
| NCT05459402Phase 3University of Maryland, BaltimoreDivided or Single Exposure (DOSE) Study | 2027-06-01 |
| NCT05766631Phase 3Friends Research Institute, Inc.Treating Polysubstance Use Using a Novel Digital Technology | 2027-06-30 |
Add all 129 to your calendar (.ics) → With an account.
Among the 1,223 studies in Opioid-Related Disorders with a site in United States, from their registry updates:
This tab as a report to print or save as PDF → With an account.
Northern New England has among the highest rates of opioid dependence in the U.S. This region also has among the highest rates of opioid-related deaths in the U.S., with a disproportionate high rate among pregnant women with opioid use disorder. Newborns impacted by OUD have increased risk of poor outcomes, including preterm birth and long hospitalization for neonatal withdrawal and other newborn complications. For pregnant women with OUD, medication treatment (MOUD) significantly reduces these risks. Many maternity care providers have begun to prescribe MOUD in their practices. Other practices have maintained the longstanding evidence-based standard of care, referral of patients with OUD to specialty treatment programs. Most pregnant women with OUD have other psychosocial needs, ranging from lack of housing and untreated mental health conditions, to need for parenting education and support. There is variability among practices in terms of types of other services provided to patients. Although pregnancy is a time when women are highly motivated to start MOUD, many women are also likely to discontinue MOUD postpartum due to loss of insurance coverage, difficulty transitioning to another provider, loss of motivation for treatment, or competing demands on time and resources as a new parent.
The challenge for patients, providers, and other stakeholders is to understand the relative advantage of the two MOUD models (receiving MOUD as part of maternity care or at a specialty program) for improving key outcomes for baby \& mother. A second challenge is to understand the relative contributions of onsite services such as mental health care, care coordination and parenting education to improved outcomes. Addressing these challenges is particularly important in rural areas where obstetric practices \& specialty care services are limited. Patients, providers \& other stakeholders need guidance in choosing the optimal models for building programs to provide maternity care for women with OUD.
Northern New England has among the highest rates of opioid dependence in the U.S, with prevalence highest and growing among those aged 18-35 years. Regional rates of perinatal opioid use disorders (OUD) reflect this public health crisis; Northern New England region has the highest incidence of opioid-related births in the nation. Perinatal opioid use disorders impact 5-8% of pregnancies in Maine, New Hampshire, and Vermont, three states that have been severely impacted by the current opioid epidemic. Consequences of inadequately treated OUD include premature delivery and other perinatal complications, prolonged newborn hospitalization for neonatal abstinence (NAS), and maternal morbidity and mortality from infectious disease and overdose. In 2013, costs associated with NAS treatment in the U.S. reached $1.5 billion. The epidemic has grown multifold since 2013.
Medication assisted treatment (MAT) with either methadone or buprenorphine is the recommended standard of care during pregnancy. Professionals, including the American College of Obstetricians and Gynecologists (ACOG), the American Academy of Pediatrics, the Society for Maternal-Fetal Medicine, and the American Society for Addiction Medicine, have called to adopt care models that promote early identification and treatment for pregnant women with OUD. Referral to specialty programs for MAT has been the accepted standard of care, with demonstrated safety for women and their infants. However, in response to the escalating opioid crisis, the ACOG began offering buprenorphine training programs to its members. Consequently, a number of maternity care practices throughout Northern New England now provide integrated MAT services. But even where such integrated programs exist, questions persist on the optimal care model for providing MAT to pregnant women with OUD.
There are patient- and provider- factors associated with variability in effectiveness of what MAT model works best for whom. For women, advantages of buprenorphine over methadone include a lower risk of overdose, fewer drug interactions, the accessibility of office-based treatment delivery in the context of maternity care and demonstrated shorter NAS course. The disadvantages of buprenorphine relative to methadone include potential hepatic dysfunction, lack of long-term data on consequences of fetal exposure for infants, potential limited efficacy in patients with high addiction severity, requirement of moderate withdrawal symptoms prior to initiation to avoid iatrogenic withdrawal, and an increased risk of diversion (i.e., sharing or sale). Despite buprenorphine's demonstrated neonatal advantages, it is not effective for all women. The structure of methadone treatment (daily meeting) may also better align with support needs for some women. For providers, the choice of what medication-assisted approach to offer to patients is often restricted by availability and access to specialty care services.
There is limited literature comparing the effectiveness of integrated versus referral MAT care models for postpartum retention in treatment and women's experiences in these two models. In particular, women with high levels of addiction severity or co-occurring mental health conditions may have prenatal care needs from women with less complex behavioral health concerns. Studies have also not assessed the impact of maternal opioid addiction severity on newborn outcomes and maternal long-term recovery. The best neonatal outcomes will be achieved by providing the most appropriate and effective treatment for mothers.
The challenge for patients, providers, and other stakeholders is determining the optimal approach for delivering MAT during pregnancy and after delivery to improve outcomes. Currently, regional obstetrical practices provide either: (1) Integrated care, in which MAT and associated psychosocial services are delivered on site with obstetrical care, and (2) Referral-based care, in which women receive MAT and obstetrical care in separate, specialized locations. Both models have different potential advantages and disadvantages for mothers with OUD and their babies regarding access, availability, acceptability and quality of MAT, obstetrics and other needed services, and long term follow up and treatment after delivery. While pregnancy motivates women to initiate MAT, relapse to use of opioids and cessation of MAT frequently occur during the first postpartum year, placing both mother and infant at significant risk. Payers and policymakers are also seeking answers about where to invest healthcare resources to increase access to treatment for pregnant women, especially in the current opioid crisis. A disproportionate number of women with OUD are insured through the Medicaid system; Medicaid policy affects women's access to a wide range of services, from reimbursement for same-day services or care coordination, to whether a woman continues to be eligible for benefits after delivery.
Study Aims: The primary aims of this study seek to answer these important patient, provider, and policy questions by comparing the real-world effectiveness of two models of MAT delivery currently in clinical use in Maine, New Hampshire, and Vermont with respect to patient experience of care and perinatal, neonatal, and longer-term substance use treatment outcomes. The following main Comparative Effectiveness Research (CER) Patient-Centered Outcomes Research Institute (PCORI) priority questions will be addressed:
(1) Do clinical and patient-reported outcomes for pregnant and parenting women differ between integrated and referral-based MAT practice models?
To answer this question, the following Primary Specific Aims will be addressed:
Aim 1 (Clinical Outcomes Retrospective). To use clinical record data to evaluate the comparative effectiveness of Integrated and Referral-Based MAT care models on maternal and neonatal outcomes.
Aim 2 (Patient-reported Outcomes Prospective). To use patient reported data to evaluate the comparative effectiveness of Integrated and Referral -Based care models on patient-centered outcomes.
Study Description: This study will collaboratively engage 26 practices providing maternity care across Northern New England, with examples of both integrated care and referral-based models. The study population is pregnant women who receive prenatal care from any of these practices and who meet Diagnostic and Statistical Manual of Mental Disorders (DSM-5) diagnostic criteria for an opioid use disorder. A cluster-based observational mixed-methods design will be used to compare outcomes for pregnant women with opioid use disorder receiving prenatal care in obstetric practices that offer MAT through one of two delivery models: Integrated or Referral-based. Retrospective clinical records data (n=2000) from pregnant women with OUD receiving prenatal care at a partner practice will be used to examine Aim 1. Aim 2 will be addressed with a patient-report subsample cohort (n=532) recruited in the 3rd trimester of care and followed to 6 months postpartum via self-report online surveys. The analytic strategy will account for clustering and patient baseline differences to compare outcomes across arms.
Aim 1. Retrospective records from eligible women who delivered in specified time period in one of our 26 partner practices will be reviewed for specified clinical outcomes.
Aim 2. Participants will be recruited from our 26 partner maternity care practices located throughout our northeastern New England region: New Hampshire, Maine, and Vermont.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Informed consent
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
This is an observational study and no intervention will be administered. The Integrated Cohort consists of pregnant women with identified opioid use disorder who are receiving prenatal care in a maternity setting that provides medication assisted treatment for opioid use.
Other: Observational Study
This is an observational study and no intervention will be administered. The Referral-Based Cohort consists of pregnant women with identified opioid use disorder who are receiving prenatal care in a maternity setting and are referred to substance use treatment at a specialty care setting.
Other: Observational Study
No intervention will be administered.
Self Report of Medication Treatment for Opioid Use Disorder at 6 Months Postpartum (Yes)
Portion of participants who self reported receiving MOUD (yes) at 6 months postpartum.
Time frame: measured 3rd trimester, 3 months postpartum, 6 months postpartum (reported 6 months postpartum)
Number of Participants With High Self Reported Depression Symptoms (Moderate to Severe) From Baseline to 6 Months Postpartum
* Full unabbreviated scale name: Edinburgh Postnatal Depression Scale * Maximum and minimum scores: 0-30, higher indicates more severe symptoms * Scoring and interpretation of values: Binary variable (0/1) was created based on established cutoffs: \<=14 = 0 low symptoms/\>14=1 moderate to high symptoms
Time frame: assessed at 3rd trimester, 3 months postpartum and 6 months postpartum (reported 6 months postpartum)
Change in Number of Participants That Self Reported Anxiety: Moderate to Severe From Baseline to 6 Months Postpartum
* Full unabbreviated scale name: Generalized Anxiety Disorders Scale- 7 * Maximum and minimum scores: 0-21, higher indicates more severe symptoms * Scoring and interpretation of values: 7-item scale with each item scored from 0 (not at all) to 3 (nearly every day), results are summed to calculate overall score. Score \>=10 is considered clinically significant anxiety symptomatology: https://www.mdcalc.com/gad-7-general-anxiety-disorder-7 Binary variables were created for analyses: \< =9 = 0 Low; \>9 = 1 High
Time frame: Assessed at 3rd trimester, 3 months postpartum and 6 months postpartum (reported 6 months postpartum).
Self Reported Prenatal Care Experience
Instrument: Experience of Care module of the Consumer Assessment of Healthcare Providers and Systems (CAHPS) Clinician and Groups Survey, 28 items measured on 1-5 Likert, high scores indicative of more positive perceptions. A total score was created by averaging the items on the 5-point response scale, with high scores indicative of more positive patient-centered care perceptions. (range: 1-5).
Time frame: 3rd Trimester
Medication Treatment for Opioid Use Disorder Yes at Delivery
Retrospective Cohort: Medical record indication of medication for opioid use disorder as noted in medication list or notes at delivery
Time frame: Single Point - Delivery
Non-prescribed Opioid Use at Delivery (Yes)
Retrospective: Indicator of non-prescribed opioid use at delivery as indicated by positive drug screen at delivery or problem notes.
Time frame: Single Timepoint: Delivery
Perinatal Complications (Yes)
Indications of perinatal complications as indicated by any of the following in the antenatal period: pre-eclampsia, fetal growth \<10% intrauterine growth restriction. miscarriage, fetal demise, bleeding, placental abruption, deep vein thrombosis
Time frame: Single Point, at Delivery
Change in Self Reported Physical Quality of Life From 3rd Trimester to 6 Months Postpartum
Quality of Life was assessed with the 28-item WHOQOL Bref, a well-established and frequently used instrument in health services research, including with substance use affected populations.33,34 Items reflect 4 domains: Physical (7 items), Psychological (6 items), Social (3 items), Environment (8 items). Individual QOL domain scores were created per the scoring protocol (range: 0-100), with higher scores indicating greater perceived quality of life in that area.
Time frame: Assessed 3rd trimester, 3 months postpartum, 6 months postpartum (6 months postpartum reported)
Change in Self Report Psychological Quality of Life From 3rd Trimester to 6 Months Postpartum
Quality of Life was assessed with the 28-item WHOQOL Bref, a well-established and frequently used instrument in health services research, including with substance use affected populations. Items reflect 4 domains: Physical (7 items), Psychological (6 items), Social (3 items), Environment (8 items). Individual QOL domain scores were created per the scoring protocol (range: 0-100), with higher scores indicating greater perceived quality of life in that area.
Time frame: Assessed 3rd trimester, 3 months postpartum, 6 months postpartum (6 months postpartum reported)
Change in Self Reported Social Quality of Life From 3rd Trimester to 6 Months Postpartum
Quality of Life was assessed with the 28-item WHOQOL Bref, a well-established and frequently used instrument in health services research, including with substance use affected populations.33,34 Items reflect 4 domains: Physical (7 items), Psychological (6 items), Social (3 items), Environment (8 items). Individual QOL domain scores were created per the scoring protocol (range: 0-100), with higher scores indicating greater perceived quality of life in that area.
Time frame: 3rd trimester, 3 months postpartum, 6 months postpartum (6 months reported)
Self-reported Retention of Child Custody Retention - Yes Responses
Self-reported Retention of Child Custody (yes/no) at 6 months postpartum
Time frame: at 6 months postpartum
Self-report Recommended Pediatric Visits Yes at 6 Months
Self-report Recommended Pediatric Visits at 6 months (Yes)
Time frame: at 6 months postpartum
Substance Use Other Than Opioid Use at Delivery(Yes)
Indication of use by positive drug screen at delivery of any of the following at delivery:
Time frame: Single timepoint, delivery
Neonatal Complications (Yes)
Indication of any neonatal complications as identified in record by birth weight \<=2500 gm, Apgar\<7 at 5 mins, Apgar \<7 at 10 mins, complications not related to neonatal opioid withdrawal syndrome (NOWS), or other noted medical problems in record.
Time frame: Single point measured at delivery
Receipt of Treatment for Neonatal Opioid Withdrawal Syndrome After Delivery (Yes)
Indication of newborn treated with pharmacological agent due to withdrawal symptoms at indicated in record.
Time frame: single time, within 2 weeks of delivery
Aim 2. Recruitment occurred July 2019 - May 2023 via flyers and referral. Participants were pregnant persons aged 16 years and older, identified OUD, receiving care in partner setting. Recruitment settings include 68 practices representative of catchment area (28: Integrated/40 Referral). Aim 1. Review of clinical records from eligible women who received prenatal care at partner practices from September 1 2015 - December 31 2022. Records were abstracted from 23/26 partner practices.
| Milestone | Integrated Care | Referral-Based Care |
|---|---|---|
| Started | 254 | 186 |
| Completed | 183 | 150 |
| Not completed | 71 | 36 |
| Withdrew: Lost to follow-up | 71 | 36 |
| Milestone | Integrated Care | Referral-Based Care |
|---|---|---|
| Started | 983 | 1087 |
| Completed | 983 | 1087 |
| Not completed | 0 | 0 |
Portion of participants who self reported receiving MOUD (yes) at 6 months postpartum.
| Participants | Integrated Care | Referral-Based Care |
|---|---|---|
| Self Report of Medication Treatment for Opioid Use Disorder at 6 Months Postpartum (Yes) | 122 | 122 |
* Full unabbreviated scale name: Edinburgh Postnatal Depression Scale * Maximum and minimum scores: 0-30, higher indicates more severe symptoms * Scoring and interpretation of values: Binary variable (0/1) was created based on established cutoffs: \<=14 = 0 low symptoms/\>14=1 moderate to high symptoms
| Participants | Integrated Care | Referral-Based Care |
|---|---|---|
| Number of Participants With High Self Reported Depression Symptoms (Moderate to Severe) From Baseline to 6 Months Postpartum | 65 | 58 |
* Full unabbreviated scale name: Generalized Anxiety Disorders Scale- 7 * Maximum and minimum scores: 0-21, higher indicates more severe symptoms * Scoring and interpretation of values: 7-item scale with each item scored from 0 (not at all) to 3 (nearly every day), results are summed to calculate overall score. Score \>=10 is considered clinically significant anxiety symptomatology: https://www.mdcalc.com/gad-7-general-anxiety-disorder-7 Binary variables were created for analyses: \< =9 = 0 Low; \>9 = 1 High
| Participants | Integrated Care | Referral-Based Care |
|---|---|---|
| Change in Number of Participants That Self Reported Anxiety: Moderate to Severe From Baseline to 6 Months Postpartum | 49 | 41 |
Instrument: Experience of Care module of the Consumer Assessment of Healthcare Providers and Systems (CAHPS) Clinician and Groups Survey, 28 items measured on 1-5 Likert, high scores indicative of more positive perceptions. A total score was created by averaging the items on the 5-point response scale, with high scores indicative of more positive patient-centered care perceptions. (range: 1-5).
| score on a scale | Integrated Care | Referral-Based Care |
|---|---|---|
| Self Reported Prenatal Care Experience | 3.64 ± .57 | 3.61 ± .56 |
Retrospective Cohort: Medical record indication of medication for opioid use disorder as noted in medication list or notes at delivery
| Participants | Integrated Care | Referral-Based Care |
|---|---|---|
| Medication Treatment for Opioid Use Disorder Yes at Delivery | 303 | 291 |
Retrospective: Indicator of non-prescribed opioid use at delivery as indicated by positive drug screen at delivery or problem notes.
| Participants | Integrated Care | Referral-Based Care |
|---|---|---|
| Non-prescribed Opioid Use at Delivery (Yes) | 19 | 24 |
Indications of perinatal complications as indicated by any of the following in the antenatal period: pre-eclampsia, fetal growth \<10% intrauterine growth restriction. miscarriage, fetal demise, bleeding, placental abruption, deep vein thrombosis
| Participants | Integrated Care | Referral-Based Care |
|---|---|---|
| Perinatal Complications (Yes) | 107 | 86 |
Quality of Life was assessed with the 28-item WHOQOL Bref, a well-established and frequently used instrument in health services research, including with substance use affected populations.33,34 Items reflect 4 domains: Physical (7 items), Psychological (6 items), Social (3 items), Environment (8 items). Individual QOL domain scores were created per the scoring protocol (range: 0-100), with higher scores indicating greater perceived quality of life in that area.
| score on a scale | Integrated Care | Referral-Based Care |
|---|---|---|
| Change in Self Reported Physical Quality of Life From 3rd Trimester to 6 Months Postpartum | 67.4 ± 1.50 | 61.6 ± 2.26 |
Quality of Life was assessed with the 28-item WHOQOL Bref, a well-established and frequently used instrument in health services research, including with substance use affected populations. Items reflect 4 domains: Physical (7 items), Psychological (6 items), Social (3 items), Environment (8 items). Individual QOL domain scores were created per the scoring protocol (range: 0-100), with higher scores indicating greater perceived quality of life in that area.
| score on a scale | Integrated Care | Referral-Based Care |
|---|---|---|
| Change in Self Report Psychological Quality of Life From 3rd Trimester to 6 Months Postpartum | 59.8 ± 1.47 | 54.3 ± 2.49 |
Quality of Life was assessed with the 28-item WHOQOL Bref, a well-established and frequently used instrument in health services research, including with substance use affected populations.33,34 Items reflect 4 domains: Physical (7 items), Psychological (6 items), Social (3 items), Environment (8 items). Individual QOL domain scores were created per the scoring protocol (range: 0-100), with higher scores indicating greater perceived quality of life in that area.
| score on a scale | Integrated Care | Referral-Based Care |
|---|---|---|
| Change in Self Reported Social Quality of Life From 3rd Trimester to 6 Months Postpartum | 60.0 ± 1.59 | 56.6 ± 3.07 |
Self-reported Retention of Child Custody (yes/no) at 6 months postpartum
| Participants | Integrated Care | Referral-Based Care |
|---|---|---|
| Self-reported Retention of Child Custody Retention - Yes Responses | 136 | 121 |
Self-report Recommended Pediatric Visits at 6 months (Yes)
| Participants | Integrated Care | Referral-Based Care |
|---|---|---|
| Self-report Recommended Pediatric Visits Yes at 6 Months | 151 | 134 |
Indication of use by positive drug screen at delivery of any of the following at delivery:
| Participants | Integrated Care | Referral-Based Care |
|---|---|---|
| Substance Use Other Than Opioid Use at Delivery(Yes) | 77 | 82 |
Indication of any neonatal complications as identified in record by birth weight \<=2500 gm, Apgar\<7 at 5 mins, Apgar \<7 at 10 mins, complications not related to neonatal opioid withdrawal syndrome (NOWS), or other noted medical problems in record.
| Participants | Integrated Care | Referral-Based Care |
|---|---|---|
| Neonatal Complications (Yes) | 117 | 133 |
Indication of newborn treated with pharmacological agent due to withdrawal symptoms at indicated in record.
| Participants | Integrated Care | Referral-Based Care |
|---|---|---|
| Receipt of Treatment for Neonatal Opioid Withdrawal Syndrome After Delivery (Yes) | 132 | 100 |
Collected over Three years.. Non-serious events are listed at a 0% frequency threshold.
| Group | Deaths | Serious | Other |
|---|---|---|---|
| Integrated Care | 0/254 (0%) | 0/254 (0%) | 0/254 (0%) |
| Referral-Based Care | 0/186 (0%) | 0/186 (0%) | 0/186 (0%) |
| Retrospective: Integrated | — | — | — |
| Retrospective: Referral | — | — | — |
| Age, Categorical(Participants) | Integrated Care | Referral-Based Care | Integrated Retrospective Cohort | Referral Retrospective Cohort | Total |
|---|---|---|---|---|---|
| <=18 years | 0 | 0 | 0 | 0 | 0 |
| Between 18 and 65 years | 254 | 186 | 983 | 1087 | 2510 |
| >=65 years | 0 | 0 | 0 | 0 | 0 |
| Age, Continuous(years) | Integrated Care | Referral-Based Care | Integrated Retrospective Cohort | Referral Retrospective Cohort | Total |
|---|---|---|---|---|---|
| Mean | 30.0 ± 5.04 | 30.3 ± 4.79 | 29.0 ± 4.72 | 28.3 ± 4.72 | 30.1 ± 5.00 |
| Sex: Female, Male(Participants) | Integrated Care | Referral-Based Care | Integrated Retrospective Cohort | Referral Retrospective Cohort | Total |
|---|---|---|---|---|---|
| Female | 254 | 186 | 983 | 1087 | 2510 |
| Male | 0 | 0 | 0 | 0 | 0 |
| Ethnicity (NIH/OMB)(Participants) | Integrated Care | Referral-Based Care | Integrated Retrospective Cohort | Referral Retrospective Cohort | Total |
|---|---|---|---|---|---|
| Hispanic or Latino | 34 | 21 | 29 | 20 | 104 |
| Not Hispanic or Latino | 220 | 165 | 930 | 1024 | 2339 |
| Unknown or Not Reported | 0 | 0 | 24 | 43 | 67 |
| Race (NIH/OMB)(Participants) | Integrated Care | Referral-Based Care | Integrated Retrospective Cohort | Referral Retrospective Cohort | Total |
|---|---|---|---|---|---|
| American Indian or Alaska Native | 2 | 3 | 0 | 0 | 5 |
| Asian | 0 | 0 | 0 | 0 | 0 |
| Native Hawaiian or Other Pacific Islander | 0 | 0 | 0 | 0 | 0 |
| Black or African American | 10 | 3 | 0 | 0 | 13 |
| White | 228 | 174 | 919 | 1037 | 2358 |
| More than one race | 0 | 0 | 38 | 10 | 48 |
| Unknown or Not Reported | 14 | 6 | 26 | 40 | 86 |
| Region of Enrollment(participants) | Integrated Care | Referral-Based Care | Integrated Retrospective Cohort | Referral Retrospective Cohort | Total |
|---|---|---|---|---|---|
| United States | 254 | 186 | 983 | 1087 | 2510 |
| Medication Treatment for OUD(Participants) | Integrated Care | Referral-Based Care | Integrated Retrospective Cohort | Referral Retrospective Cohort | Total |
|---|---|---|---|---|---|
| Count of participants | 211 | 152 | — | — | 363 |
| Self Report Depression - Moderate to Severe(Participants) | Integrated Care | Referral-Based Care | Integrated Retrospective Cohort | Referral Retrospective Cohort | Total |
|---|---|---|---|---|---|
| Count of participants | 97 | 78 | — | — | 175 |
4 further baseline measures are reported on the registry.
PDFs hosted by the registry, ClinicalTrials.gov.
Plan to share: No
Ran from Jul 2019 to primary completion in Jan 2024, 54 months.
Results were first posted in Oct 2026, 2 years 8 months after primary completion.
Of 74 non-industry observational studies under Opioid-Related Disorders, half reached primary completion within 30 months of starting (the median), counting those still running; a quarter within 13 and three quarters within 51. This study's 54 months is above that.
Counting every sponsor, half of 88 studies reached it within 27 months; a quarter within 13 and three quarters within 47.
How these figures are worked out, and which studies are left out of them.
From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗
This study is completed, as verified in Jul 2026. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Trustees of Dartmouth College